357 related articles for article (PubMed ID: 24903747)
1. Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.
Bravo GM; Lee E; Merchan B; Kantarjian HM; García-Manero G
Br J Haematol; 2014 Sep; 166(5):646-59. PubMed ID: 24903747
[TBL] [Abstract][Full Text] [Related]
2. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
3. The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317
[TBL] [Abstract][Full Text] [Related]
4. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
5. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.
Gill H; Leung AY; Kwong YL
Int J Mol Sci; 2016 Mar; 17(4):440. PubMed ID: 27023522
[TBL] [Abstract][Full Text] [Related]
6. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
[TBL] [Abstract][Full Text] [Related]
7. The molecular pathogenesis of the myelodysplastic syndromes.
Pellagatti A; Boultwood J
Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
Itzykson R; Kosmider O; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
[TBL] [Abstract][Full Text] [Related]
9. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome.
Mian SA; Smith AE; Kulasekararaj AG; Kizilors A; Mohamedali AM; Lea NC; Mitsopoulos K; Ford K; Nasser E; Seidl T; Mufti GJ
Haematologica; 2013 Jul; 98(7):1058-66. PubMed ID: 23300180
[TBL] [Abstract][Full Text] [Related]
10. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.
Wu L; Song L; Xu L; Chang C; Xu F; Wu D; He Q; Su J; Zhou L; Xiao C; Zhang Z; Zhao Y; Chen S; Li X
Tumour Biol; 2016 Apr; 37(4):4633-40. PubMed ID: 26508027
[TBL] [Abstract][Full Text] [Related]
11. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
Larsson CA; Cote G; Quintás-Cardama A
Mol Cancer Res; 2013 Aug; 11(8):815-27. PubMed ID: 23645565
[TBL] [Abstract][Full Text] [Related]
12. Genetic abnormalities and pathophysiology of MDS.
Hosono N
Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndromes: Contemporary review and how we treat.
Gangat N; Patnaik MM; Tefferi A
Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
[TBL] [Abstract][Full Text] [Related]
14. Epigenetics in myelodysplastic syndromes.
Heuser M; Yun H; Thol F
Semin Cancer Biol; 2018 Aug; 51():170-179. PubMed ID: 28778402
[TBL] [Abstract][Full Text] [Related]
15. Myeloid malignancies: mutations, models and management.
Murati A; Brecqueville M; Devillier R; Mozziconacci MJ; Gelsi-Boyer V; Birnbaum D
BMC Cancer; 2012 Jul; 12():304. PubMed ID: 22823977
[TBL] [Abstract][Full Text] [Related]
16. Clonal cytopenias of undetermined significance: potential predictor of myeloid malignancies?
Vobugari N; Heuston C; Lai C
Clin Adv Hematol Oncol; 2022 Jun; 20(6):375-383. PubMed ID: 35731608
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
[TBL] [Abstract][Full Text] [Related]
18. The genetic basis of myelodysplasia and its clinical relevance.
Cazzola M; Della Porta MG; Malcovati L
Blood; 2013 Dec; 122(25):4021-34. PubMed ID: 24136165
[TBL] [Abstract][Full Text] [Related]
19. Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.
Zahid MF; Patnaik MM; Gangat N; Hashmi SK; Rizzieri DA
Eur J Haematol; 2016 Oct; 97(4):313-20. PubMed ID: 27147278
[TBL] [Abstract][Full Text] [Related]
20. [Epigenetic dysregulation in myelodysplastic syndromes].
Sashida G
Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
